EX-23.2 7 axdx-12312024xexh232.htm EX-23.2

EXHIBIT 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statement (Form S-1 No. 333-276031) of Accelerate Diagnostics, Inc.,

(2)Registration Statement (Form S-3 No. 333-262494) of Accelerate Diagnostics, Inc.,

(3)Registration Statement (Form S-8 No. 333-187439) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,

(4)Registration Statement (Form S-8 No. 333-199992) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,

(5)Registration Statement (Form S-8 No. 333-225585) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,

(6)Registration Statement (Form S-8 No. 333-233185) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,

(7)Registration Statement (Form S-8 No. 333-239052) pertaining to the 2012 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,

(8)Registration Statement (Form S-8 No. 333-265126) pertaining to the 2022 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.,

(9)Registration Statement (Form S-8 No. 333-272792) pertaining to the 2022 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc., and

(10)Registration Statement (Form S-8 No. 333-279406) pertaining to the 2022 Omnibus Equity Incentive Plan of Accelerate Diagnostics, Inc.;

of our report dated March 28, 2024, with respect to the consolidated financial statements of Accelerate Diagnostics, Inc., included in this Annual Report (Form 10-K) of Accelerate Diagnostics, Inc. for the year ended December 31, 2024.

 

/s/ Ernst & Young LLP

Phoenix, Arizona

March 20, 2025